A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
100estimated
Sites
40
Countries
Australia, Belgium, Canada +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-29 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Recurrent Ovarian Cancer
- Folate Receptor-Alpha Positive
Interventions
- Drug: Mirvetuximab Soravtansine — also filed as IMGN853, MIRV
- Drug: Lubricating Eye Drops
- Drug: Prednisolone acetate ophthalmic suspension 1% eye drops
- Drug: Brimonidine tartrate ophthalmic solution eye drops
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With MIRV-related Corneal TEAEs (≥ Grade 2) in Asymptomatic Participants
measured Cycle 1 Day 1 up to 18 weeks or at the 30-day follow-up visit, whichever is earlier (cycle length = 21 days)
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed